Eltrombopag

In this article, we will discuss about Eltrombopag (Dosage Overview). So, let’s get started.

Indications

Treatment of Thrombocytopenia in Patients with Chronic ITP

Eltrombopag (PROMACTA) is indicated for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Treatment of Thrombocytopenia in Patients with Hepatitis C Infection

Eltrombopag (PROMACTA) is indicated for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy.

Treatment of Severe Aplastic Anemia

Eltrombopag (PROMACTA) is indicated for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.

Dosage

• Take on an empty stomach (1 hour before or 2 hours after a meal).
Chronic ITP: Initiate Eltrombopag (PROMACTA) at 50 mg once daily for most adult and pediatric patients 6 years and older and at 25 mg once daily for pediatric patients aged 1 to 5 years. Dose reductions are needed for patients with hepatic impairment and some patients of East Asian ancestry. Adjust to maintain platelet count greater than or equal to 50 x 10⁹/L. Do not exceed 75 mg per day.
Chronic Hepatitis C-associated Thrombocytopenia: Initiate
Eltrombopag (PROMACTA) at 25 mg once daily for all patients. Adjust to achieve target platelet count required to initiate antiviral therapy. Do not exceed a daily dose of 100 mg.
Severe Aplastic Anemia: Initiate Eltrombopag (PROMACTA) at 50 mg once daily for most patients. Reduce initial dose in patients with hepatic impairment or patients of East Asian ancestry. Adjust to maintain platelet count greater than 50 x 10⁹/L. Do not exceed 150 mg per day.
.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.